00143-9098-01, 00409-1700-01, 10019-0991-01, 25021-0244-10, 50742-0484-01, 55150-0337-01, 60505-6050-04, 63020-0049-01, 63323-0821-10, 68001-0534-36, 68001-0540-36, 70710-1411-01, 70860-0225-10, 43598-0426-60,
Route of Administration:
BORTEZOMIB is a Cancer drug manufactured by Bluepoint Laboratories and administered via the Injection route of administration. The J Code: J9041 is aligned to the drug BORTEZOMIB.
Bortezomib is an anti-cancer drug which inhibits rapid cell growth. This drug is administered by a doctor or a healthcare professional via injection into a vein. Bortezomib is a generic drug that is produced by multiple manufacturers including Fresenius Kabi, Hospira, Bluepoint Laboratories, Baxter, and others. Fresenius Kabi (J9048) and Hospira (J9049) each have their own unique HCPCS for Bortezomib distinct from the generic HCPCS code (J9041). Takeda Pharmaceuticals offers patient support for Velcade here: https://www.velcade.com/support-from-takeda/. Fresenius Kabi offers patient support for Bortezomib here: https://kabicare.us/patient/.